The Use of Active Centre Acylation to Control the Pharmacokinetic Profile of a Recombinant Chimaeric Plasminogen Activator

Summary

Recombinant hybrid plasminogen activators consisting of the “A” chain of plasminogen linked to the “B” chain of t-PA that are inhibited rapidly by plasma protease inhibitors have recently been described (Robinson et al. Circulation 1992; 86: 548-552). We have now shown that following bolus administration of native hybrid to guinea pigs, fibrinolytic activity was cleared rapidly from the circulation. Active centre acylation appeared to protect the hybrid from inhibition and allowed material to circulate as potentially active species for prolonged periods. Clearance rates of a range of acyl derivatives of the hybrid were 7-35-fold slower than for native hybrid and 20-100-fold slower than for t-PA. Clearance rates were influenced markedly by deacylation rate, such that clearance half-life correlated well with deacylation halflife. We have thus shown that it is feasible to control the pharmacokinetic profile of a recombinant hybrid plasminogen activator over a wide range by selection of an appropriate acyl group for attachment to the active site. Such control is not possible with plasminogen activators that are cleared predominantly by mechanisms other than inhibition.

• References

• 1 Robinson JH, Browne MJ. Redesigning t-PA for improved thrombolytic therapy. TIBTECH 1991; 9: 86-90
• 2 Higgins DL, Bennett WF. Tissue Plasminogen Activator: The biochemistry and pharmacology of variants produced by mutagenesis. Annu Rev Pharmacol Toxicol 1990; 30: 091-121
• 3 Fears R, Ferres H, Standring R. The protective effect of acylation on the stability of anisoylated plasminogen streptokinase activator complex in human plasma. Drugs 1987; 33 (Suppl. 03) 57-63
• 4 Esmail AF, Dupe RJ, English PD, Smith RAG. Pharmacokinetic and pharmacodynamic comparisons of acylated streptokinase-plasminogen complexes with different deacylation rate constants. Progress in Fibrinolysis 1985; 7: 235-240
• 5 Nunn B, Esmail AF, Fears R, Ferres H, Standring R. Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and humans. Drugs 1987; 33 (Suppl. 03) 88-92
• 6 Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl enzymes: a new approach to thrombolytic therapy. Nature 1981; 290: 505-508
• 7 Dupe RJ, Green J, Smith RAG. Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. Thromb Haemostas 1985; 53: 56-59
• 8 Smith RAG. Acyl-enzymes as fibrinolytic pro-drugs. Progress in Fibrinolysis 1983; 6: 232-239
• 9 Green J, Harris GS, Smith RAG, Dupe RJ. Acyl-enzymes: a novel class of thrombolytic agents. In: Thrombolysis: Biological and therapeutic properties of new thrombolytic agents. Collen D, Lijnen HR, Verstraete M. (eds). Edinburgh: Churchill Livingstone; 1985: 124-167
• 10 Wilson S, Chamberlain P, Dodd I, Esmail AF, Robinson J. Interaction of a plasmin A-chain/t-PA B-chain hybrid enzyme with plasma protease inhibitors in vivo and in vitro. Thromb Haemostas 1990; 63: 459-463
• 11 Robinson JH, Browne MJ, Carey JE, Chamberlain PD, Chapman CG, Cronk DW, Dodd I, Entwisle C, Esmail AF, Kalindjian SB, Lawrence GMP, McMurdo L, Mitchell D, Smith RAG, Wilson S. A recombinant chimaeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activator. Circulation 1992; 86: 548-552
• 12 Robinson JH. Novel mechanism of action of a recombinant plasminogen/t-PA hybrid protein. Third International Workshop on the molecular and cellular biology of plasminogen activation. Elsinore; Denmark: 1991. Abstract 84
• 13 Browne MJ, Robinson JH, Smith RAG, Kalindjian SB. Hybrid plasminogen activators. European patent application. 1989; 0, 297: 882
• 14 Browne MJ, Dodd I, Crey JE, Chapman CG, Robinson JH. Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology. Thromb Haemostas 1985; 54: 422-424
• 15 Smith RAG. Enzyme derivatives. US patent. 1981; 4 (285) 932
• 16 Smith RAG, Dupe RJ, English PD, Green J. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis. Thromb Haemostas 1982; 47: 269-274
• 17 Smith RAG. Pharmacologically active compounds. US patent. 1985; 4 (507) 283
• 18 Dodd I, Fears R, Robinson JH. Isolation and preliminary characterisation of active B-chain of recombinant tissue-type plasminogen activator. Thromb Haemostas 1986; 55: 94-97
• 19 Allen GD. MODFIT: A pharmacokinetic computer programme. Biopharm & Drug Dispos 1990; 11: 477-498
• 20 Laemmli UK. Cleavage of structural proteins during the assembly of the head of Bacteriophage T4. Nature 1970; 227: 680-685
• 21 Granelli-Piperno A, Reich E. A study of proteases and proteaseinhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234
• 22 Markwardt F, Wagner G, Walsmann P, Horn H, Stuerzebecher J. Inhibition of trypsin and thrombin by amidinophenyl esters of aromatic carboxylic acids. Acta Biologica et Medica Germanica 1972; 28: K19-K25
• 23 Tanizawa K, Kasaba Y, Kanoaka Y. “Inverse substrates” for trypsin. Efficient enzymatic hydrolysis of certain esters with a cationic center in the leaving group. Journal of the American Chemical Society 1977; 99: 4485-4488
• 24 Smith RAG, Garman AJ, Morgan GS. Structure-activity relationships for the formation and breakdown of acylated fibrinolytic enzymes. Progress in Fibrinolysis 1985; 7: 227-231
• 25 Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978; 272: 549-550
• 26 Ferres H, Hibbs M, Smith RAG. Deacylation studies in vitro on anisoylated plasminogen streptokinase activator complex. Drugs 1987; 33 (Suppl. 03) 80-82
• 27 Lijnen HR, Van HoefB, De CockF, Okada K, Ueshima S, Matsuo O, Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-11832
• 28 Kalindjian SB, Smith RAG. Reagents for reversible coupling of proteins to the centres of trypsin-like serine proteases. Biochem J 1987; 248: 409-413
• 29 Smith RAG, Cassels R. Preparation and properties of a reversible conjugate of immunoglobulin G with the active centre of human tissue plasminogen activator. Fibrinolysis 1988; 2: 189-195